PURPOSE: To determine the vitreous levels of angiopoietin (Ang)-1 and Ang-2 in eyes with retinopathy of prematurity (ROP), and to determine the correlation between the 2 levels. DESIGN: Retrospective case-control study. METHODS: Forty-eight eyes with stage 4 ROP were studied. Six eyes with congenital cataract were used as controls. The ROP eyes were classified by the vascular activity into highly (n = 22), moderately (n = 15), and mildly (n = 11) vascular-active ROP. Eyes with highly vascular-active ROP initially received 0.5 mg of intravitreal bevacizumab (IVB) and underwent vitrectomy within 1 week. The others underwent vitrectomy without IVB. Vitreous samples were collected at the beginning of vitrectomy, and the vitreous levels of Angs were measured by enzyme-linked immunosorbent assay. RESULTS: The mean concentrations of Ang-1 and Ang-2 were 201.9 and 7832.1 pg/mL in highly vascular-active ROP eyes, 216.1 and 7731.2 pg/mL in moderately vascular-active ROP eyes, 533.8 and 1685.9 pg/mL in mildly vascular-active ROP eyes, and 0 and 41.5 pg/mL in control eyes. The vitreous Ang-1 level was significantly higher (P < .05) in highly, moderately, and mildly vascular-active ROP eyes than in control eyes. The vitreous Ang-2 level was significantly higher (P < .05) in highly and moderately vascular-active ROP eyes than in control eyes. There was a significant negative correlation (r = -0.406; P = .040) between the Ang-1 and Ang-2 levels in moderately and mildly vascular-active ROP eyes. CONCLUSIONS: The balance of Ang-1 and Ang-2 in the vitreous may be important in the pathogenesis of ROP.
PURPOSE: To determine the vitreous levels of angiopoietin (Ang)-1 and Ang-2 in eyes with retinopathy of prematurity (ROP), and to determine the correlation between the 2 levels. DESIGN: Retrospective case-control study. METHODS: Forty-eight eyes with stage 4 ROP were studied. Six eyes with congenital cataract were used as controls. The ROP eyes were classified by the vascular activity into highly (n = 22), moderately (n = 15), and mildly (n = 11) vascular-active ROP. Eyes with highly vascular-active ROP initially received 0.5 mg of intravitreal bevacizumab (IVB) and underwent vitrectomy within 1 week. The others underwent vitrectomy without IVB. Vitreous samples were collected at the beginning of vitrectomy, and the vitreous levels of Angs were measured by enzyme-linked immunosorbent assay. RESULTS: The mean concentrations of Ang-1 and Ang-2 were 201.9 and 7832.1 pg/mL in highly vascular-active ROP eyes, 216.1 and 7731.2 pg/mL in moderately vascular-active ROP eyes, 533.8 and 1685.9 pg/mL in mildly vascular-active ROP eyes, and 0 and 41.5 pg/mL in control eyes. The vitreous Ang-1 level was significantly higher (P < .05) in highly, moderately, and mildly vascular-active ROP eyes than in control eyes. The vitreous Ang-2 level was significantly higher (P < .05) in highly and moderately vascular-active ROP eyes than in control eyes. There was a significant negative correlation (r = -0.406; P = .040) between the Ang-1 and Ang-2 levels in moderately and mildly vascular-active ROP eyes. CONCLUSIONS: The balance of Ang-1 and Ang-2 in the vitreous may be important in the pathogenesis of ROP.
Authors: Jing Chen; Jean-Sebastian Joyal; Colman J Hatton; Aimee M Juan; Dorothy T Pei; Christian G Hurst; Dan Xu; Andreas Stahl; Ann Hellstrom; Lois E H Smith Journal: Invest Ophthalmol Vis Sci Date: 2012-05-17 Impact factor: 4.799
Authors: Ryan Swan; Sang Jin Kim; J Peter Campbell; R V Paul Chan; Kemal Sonmez; Kent D Taylor; Xiaohui Li; Yii-Der Ida Chen; Jerome I Rotter; Charles Simmons; Michael F Chiang Journal: Ophthalmol Retina Date: 2018-03-08
Authors: Joyce J T Chan; Carol P S Lam; Madeline K M Kwok; Raymond L M Wong; Gary K Y Lee; Winnie W Y Lau; Jason C S Yam Journal: Sci Rep Date: 2016-06-01 Impact factor: 4.379